By Industry Analysis Desk
Published September 28, 2026
In a strategic recalibration that underscores the intensifying competition within the oncology space, Merck & Co. has opted to withdraw its regulatory submission for the antibody-drug conjugate (ADC) known as “I-DXd.” The decision, which marks a significant setback for the pharmaceutical giant’s efforts to diversify its pipeline ahead of the looming patent cliff for its flagship therapy, Keytruda, highlights the brutal efficiency of the modern drug development race.
As Merck looks toward a future beyond its multi-billion-dollar immunotherapy, its reliance on ADCs—often described as "guided missiles" of cancer treatment—has become a cornerstone of its long-term growth strategy. However, the withdrawal of I-DXd suggests that the bar for entry into the treatment of small-cell lung cancer (SCLC) has been raised, leaving investors and industry analysts to recalibrate their expectations for the company’s clinical prospects.
The Core Conflict: A Shifting Standard of Care
At the heart of the issue is the B7-H3 protein, a target that has become the focus of a fierce battle in oncology. B7-H3 is frequently overexpressed in SCLC, a particularly aggressive form of lung cancer characterized by rapid growth and a grim prognosis for patients with “extensive” disease—cases where the cancer has metastasized beyond the primary site.
For Merck, the development of I-DXd, in partnership with Daiichi Sankyo, was intended to secure an early foothold in this difficult-to-treat indication. Yet, recent clinical data presentations have painted a challenging picture for the drug. While Merck’s candidate demonstrated efficacy, it has been dogged by safety concerns, particularly regarding interstitial lung disease (ILD)—a serious and potentially fatal inflammatory condition of the lungs.
Conversely, rival programs from competitors like GSK and Roche have begun to show more favorable profiles. Data from Phase 3 trials in China for candidates licensed to these firms suggest that they can outperform standard chemotherapy while avoiding the severe toxicity markers that have hindered I-DXd.
Chronology: The Road to the Withdrawal
The journey of I-DXd to its current impasse has been marked by high-stakes partnerships and the volatility of clinical trial readouts.
- Pre-2026: Merck aggressively builds its ADC portfolio, signing high-profile licensing agreements with Daiichi Sankyo and Kelun-Biotech to diversify beyond Keytruda.
- Early 2026: Initial optimism surrounds the potential for I-DXd to receive accelerated approval, a regulatory pathway that would have allowed Merck to reach the market ahead of competitors.
- Mid-2026: At major medical conferences, data emerges from competitors’ trials, specifically those involving B7-H3-targeting ADCs, which set a higher benchmark for safety and efficacy.
- September 2026: Facing increasing scrutiny from the FDA regarding the “limited” results underlying their submission, and acknowledging the progress of rival firms, Merck and Daiichi Sankyo announce the withdrawal of the regulatory application for I-DXd.
- Current Status: GSK has already commenced global clinical testing of its candidate, "riz-rez," while Roche is expected to follow suit with "tam-peli."
Supporting Data and The Competitive Gap
The decision to pull the application was not entirely unexpected by market observers. RBC Capital Markets analyst Trung Huynh noted that the progress of rival programs, combined with the earlier clinical hurdles faced by I-DXd, had led many investors to assign minimal value to the asset.
The Safety Profile Comparison
The crux of the clinical dilemma lies in the therapeutic index. Evidence presented at recent medical meetings suggests that both GSK’s riz-rez and Roche’s tam-peli demonstrate superior safety profiles. For regulators, the presence of drug-induced ILD in the I-DXd studies became an increasingly difficult hurdle to clear, especially as cleaner alternatives reached the trial stage.
The Bar for Success
The landscape for SCLC treatment has been permanently altered by the entry of novel therapies. Cantor Fitzgerald analyst Li Watsek pointed out that the recent FDA approval of Amgen’s Imdelltra has essentially reset the expectations for clinical efficacy. To gain regulatory approval now, new entrants must demonstrate a truly meaningful advantage over current standards—a bar that, according to the current data, I-DXd struggles to meet.
Official Responses and Strategic Rationale
Merck has remained characteristically pragmatic in its communications. While the withdrawal of the I-DXd application is a setback, the company maintains a broad portfolio of ADCs, including "sac-TMT," which remains a high-priority asset. Merck executives have previously identified sac-TMT as a "cornerstone" therapy, currently being evaluated across 17 global trials.
The collaborative nature of these developments—often involving co-development with Daiichi Sankyo—allows Merck to share the financial and clinical risk. However, the decision to withdraw indicates a willingness to cut losses when a program is unlikely to achieve a competitive market position. This is a crucial element of Merck’s "capital allocation" strategy, ensuring that resources are diverted to the most promising assets rather than being tied up in programs that face an uphill regulatory battle.
Implications: The Future of SCLC and Beyond
The fallout from this withdrawal extends far beyond the immediate disappointment of the I-DXd program.
1. The Rise of New Leaders
The shift in momentum has provided an opening for other players. Zai Lab, with its candidate "zoci," is currently in pivotal testing and is now positioned to potentially become the first ADC to receive approval for SCLC. Similarly, Ideaya Biosciences is moving rapidly, with plans to initiate late-stage trials by the end of 2026.
2. A New Era of Scrutiny
The FDA’s stance on this submission confirms a broader trend of increased regulatory rigor. Agencies are becoming less tolerant of "limited" results in accelerated approval pathways, particularly when competing, safer, or more effective options are in the pipeline. Manufacturers must now come to the table with robust, high-quality data from the outset.
3. Merck’s Post-Keytruda Strategy
For Merck, the message is clear: the transition away from Keytruda dominance will not be a seamless, singular success story. It will be a marathon of clinical wins and losses. While I-DXd has faltered, the company’s commitment to the ADC space remains absolute. With ongoing Phase 3 trials for I-DXd in prostate cancer and esophageal squamous cell carcinoma, the drug’s story is not over; rather, it is being refocused on indications where its efficacy profile may be more competitive.
4. Market Sentiment
For investors, the withdrawal serves as a reminder of the inherent volatility in the biopharma sector. The market is increasingly sophisticated, punishing companies that lag in safety or efficacy while rewarding those—like GSK and Roche—that provide clear evidence of "best-in-class" potential.
Conclusion
The withdrawal of I-DXd is a sober reminder that in the hyper-competitive world of oncology, clinical development is a moving target. As the scientific community hones in on proteins like B7-H3, the race to provide safer, more effective treatments for small-cell lung cancer continues to accelerate. Merck’s ability to pivot, maintain its robust partnership network, and prioritize its most viable assets will ultimately determine its success in the coming decade. As the industry looks ahead, the focus shifts to the upcoming data readouts from the next generation of ADC candidates, all of which are now operating under the high-pressure shadow of a heightened standard of care.
About the Author
